{"id":"W2948612418","doi":"10.1016/s0140-6736(19)31149-3","title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3040,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute; Université Laval; University of Toronto; Hamilton Health Sciences; McMaster University","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Type 2 diabetes; Internal medicine; Clinical endpoint; Placebo; Population; Myocardial infarction; Diabetes mellitus; Stroke (engine); Adverse effect; Semaglutide; Randomized controlled trial; Physical therapy; Exenatide; Liraglutide; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}